CHRS

Business Context and Reporting Period

Company: Coherus Oncology, Inc. (CHRS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Coherus is a commercial-stage innovative oncology company focused on its approved PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline of two mid-stage clinical candidates (casdozokitug and tagmokitug). The company has divested its biosimilar businesses (UDENYCA, YUSIMRY, CIMERLI), which are now reported as discontinued operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue from continuing operations increased 62% year-over-year to $12.3 million, driven primarily by volume growth of LOQTORZI. Gross margin improved to 69% from 65%.
• Expense Reduction: R&D expenses decreased by $2.8 million (12%) and SG&A expenses decreased by $2.9 million (11%), attributed to lower headcount and reduced operating costs following the exit from the biosimilar business.
• Discontinued Operations: Net loss from discontinued operations improved significantly to $(1.4) million from $(9.2) million, reflecting the completion of the UDENYCA sale in April 2025 and the absence of prior-year derivative liability charges.
• Capital Raise: The company completed a public offering in February 2026, issuing 32.89 million shares and raising net proceeds of $53.6 million.
• Inventory Capitalization: The company commenced capitalizing inventory costs for LOQTORZI produced in the U.S. during Q1 2026 following regulatory approval of the manufacturing process.

Guidance, Outlook, and Risks

• Outlook: Management expects net revenue from continuing operations in 2026 to be higher than in 2025 due to continued LOQTORZI growth. Fixed R&D and SG&A expenses are expected to be lower in 2026 compared to 2025.
• Liquidity: As of March 31, 2026, the company held $167.0 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months.
• Key Risks:
  • Profitability: The company has a limited history of profitability and an accumulated deficit of $1.4 billion. Future profitability depends on LOQTORZI sales growth and the success of pipeline candidates.
  • Competition: LOQTORZI faces significant competition in the nasopharyngeal carcinoma (NPC) market from established anti-PD-1/PD-L1 therapies and new entrants (e.g., Penpulimab approved in April 2025).
  • Regulatory & Manufacturing: Risks include FDA disruptions, manufacturing supply chain issues, and the transition of biomanufacturing from offshore to onshore facilities.
  • Healthcare Reform: The Inflation Reduction Act (IRA) and the One Big Beautiful Bill Act (OBBBA) may impact pricing, reimbursement, and Medicaid funding.
• Contingencies: The company is eligible for two potential earnout payments of $37.5 million each from the UDENYCA sale, contingent on future net sales thresholds.

Investor Verification Checklist

• LOQTORZI Sales Trajectory: Verify the sustainability of the 62% revenue growth rate and market share gains in the NPC indication against competitors.
• Cash Burn Rate: Assess the net cash used in operating activities ($57.9 million in Q1 2026) against the $167 million liquidity position to confirm the 12-month runway.
• Manufacturing Transition: Monitor the progress and cost implications of onshoring biomanufacturing for LOQTORZI and pipeline candidates.
• Pipeline Milestones: Track clinical progress for casdozokitug (HCC) and tagmokitug (HNSCC, mCRPC) and potential ex-U.S. licensing deals.
• UDENYCA Earnouts: Evaluate the likelihood of achieving the $300 million and $350 million net sales thresholds required for the $75 million in potential earnout payments.